Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

Macular Diseases

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

JAMA Ophthalmol.

Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S

doi: 10.1001/jamaophthalmol.

Macular Diseases

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

JAMA Ophthalmol.

Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU

doi: 10.1001/jamaophthalmol.

COMMENTED

Macular Diseases

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial

★ 3 Recommended by Prof. Dr Daniel Barthelmes, Faculty Member

★ 3 Recommended and commented by Prof. Dr Stephan Michels, Faculty Member

JAMA Ophthalmol.

Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T

doi: 10.1001/jamaophthalmol.2019.5540.

Macular Diseases

Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial

JAMA Ophthalmol.

Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew A, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel D, Desai R, MERLOT Study Group

doi: 10.1001/jamaophthalmol.

Macular Diseases

Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial

JAMA Ophthalmol.

Ramakrishnan MS, Yu Y, VanderBeek BL

doi: 10.1001/jamaophthalmol.2019.4577.

COMMENTED

Cornea and Corneal DiseasesMacular Diseases

Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration

★ 2 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Ophthalmology

Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S, COLUMBUS-AMD Study Group.

doi: 10.1016/j.ophtha.2021.04.031

Macular Diseases

Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

JAMA Ophthalmol.

Hsu J, Patel SN, Wolfe JD, Shah CP, Chen E, Jenkins TL, Wibbelsman TD, Obeid A, Mikhail M, Garg SJ, Ho AC, Chiang A, Spirn MJ, Vander JF

doi: 10.1001/jamaophthalmol.2020.0724.

COMMENTED

Macular Diseases

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

★ 2 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Br J Ophthalmol

Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnička J, Vajas A, Papp A, Vogt G, Luu J, Matuskova V, Yoon YH, Pregun T, Kim T, Shin D, Oh I, Jeong H, Kim MY, Woo SJ

doi: 10.1136/bjophthalmol-2021-319637

COMMENTED

Macular Diseases

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

JAMA Ophthalmol.

Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL

doi: 10.1001/jamaophthalmol.

Related content

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial

Evaluation of Month-24 Efficacy and Safety of Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration: The MERLOT Randomized Clinical Trial

Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial

Efficacy and Safety of Biosimilar FYB201 Compared With Ranibizumab in Neovascular Age-Related Macular Degeneration

Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial

Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes

Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial